ALEC alector.com: EV/EBITDA Multiple
Alector, Inc. (ALEC) focuses on developing cutting-edge methods to combat neuronal degeneration by leveraging the brain's immune defense potential. Its status as a biopharmaceutical pioneer is evidenced by colossal expenditures on scientific research to create specific antibodies. The EV/EBITDA valuation currently stands at 4.89. However, business success is constrained by a dependence on external grants and the probability of negative results during medical trials.
Comprehensive metric breakdowns and analytics for alector.com (ALEC)
- current price and projected stock value:
- company stock capitalization data:
- issuer book value statistics:
- debt level and financial liquidity data:
- net income and valuation multiples indicators:
ALEC - Net Income|Future Profit Alector, Inc.|ALEC - Business Payback Period|Forward P/E Multiple Alector|ALEC - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alector, Inc.|ALEC - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Alector|ALEC - Net earnings per one share for the last twelve months|Quarterly EPS earnings growth alector.com|ALEC - Net earnings per share growth this year|Net earnings per share growth forecast for next year Alector, Inc.
Summary company analysis:Alector Therapeutics ALEC
The EV/EBITDA multiple compares the total enterprise value of a business with its operating profit before interest and taxes. For Alector, Inc. (ALEC), whose resources are focused on high-risk clinical trials, this metric exposes the dependence of capitalization on the efficiency of drug development. The trend of the company's EV/EBITDA value on this chart allows for an assessment of asset overvaluation relative to actual cash flow. Long-term consensus calls for caution due to the high binary nature of test results.
Analysis of competing companies
EV/EBITDA Multiple BIIB (Biogen Corp)|Neurocrine Corp (NBIX) - Company Value to EBITDA|Regencell Bioscience - EV/EBITDA Multiple|axsome.com (AXSM) - Enterprise Value to EBITDA Ratio|ACAD (ACADIA Pharmaceuticals Inc.) - Enterprise Value to EBITDA Ratio|XENE: Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Viking Pharma|Company Value to EBITDA Supernus Corp SUPN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Catalyst Pharmaceuticals (CPRX)|DNLI (denalitherapeutics.com) - Business Value to Operating Income Before Depreciation|Harmony Biosciences Holdings, Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHVN|Amylyx - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Trevi Corp TRVI|Praxis Precision Medicines (PRAX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation AVXL|CBLL (CeriBell) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Prothena Corporation PLC (PRTA)|Enterprise Value to EBITDA Ratio ANNX (Annexon Inc.)|Total Company Value to Operating Income Before Depreciation Ratio omeros.com|EV/EBITDA Multiple NGNE (Neurogene Inc.)|EV/EBITDA Multiple acimmune.com ACIU|VYGR - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NMRA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|SCLX: EV/EBITDA Multiple|Company Value to EBITDA Tevogen Bio Inc. (TVGN)|ACOG (Alpha Cognition Inc) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio cogrx.com (CGTX)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Inhibikase Therapeutics, Inc. (IKT)|Cassava Sciences Inc - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple ASRT (Assertio)|Coya Therapeutics Inc (COYA) - Company Value to EBITDA|VTGN: Enterprise Value to EBITDA Ratio|OVID - EV/EBITDA Multiple|Acumen Pharmaceuticals, Inc. (ABOS) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CervoMed, Inc. - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Alterity Therapeutics Ltd.|Company Value to EBITDA Clene Nanomedicine CLNN|EV/EBITDA Multiple PEPG|EV/EBITDA Multiple jupiterneurosciences.com (JUNS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Relmada Therapeutics, Inc. RLMD|Annovis Bio Inc - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Grace Tx - EV/EBITDA Multiple|Company Value to EBITDA Firefly Neuro|KLTO: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio NeuroSense Therapeutics Ltd.|Enterprise Value to EBITDA Ratio RVPH|MTVA (MetaVia, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization NeurAxis, Inc (NRXS)|HSDT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Passage Bio PASG|Business Value to Operating Income Before Depreciation NEUP|NERV: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation ATHA (Athira Pharma Inc)|ADXN: EV/EBITDA Multiple|ALZN - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cyclerion Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation PTIX (Protagenic)|EV/EBITDA Multiple KTTA|Enterprise Value to EBITDA Ratio cortigent.com CRGT|Avenue Therapeutics, Inc - Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio BrainStorm Cell Therapeutics Inc. (BCLI)|Cara Therapeutics, Inc. - EV/EBITDA Multiple|CHRO - EV/EBITDA Multiple|eliemtx.com (ELYM) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ITCI (Intra-Cellular Therapies, Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|LBPH (Longboard Pharma) - EV/EBITDA Multiple|Company Value to EBITDA Marinus Pharma MRNS|EV/EBITDA Multiple NKGN|Enterprise Value to EBITDA Ratio neurobopharma.com NRBO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sage Therapeutics SAGE|SNPX: Enterprise Value to Operating Income Before Depreciation|Trevena, Inc - EV/EBITDA Multiple|Company Value to EBITDA Vigil Neuroscience|WENA (Anew Medical, Inc.) - Enterprise Value to EBITDA Ratio|cerevel.com (CERE) - EV/EBITDA Multiple
